ReviewJournal of bone and mineral metabolism2021
Sclerostin: from bench to bedside.
Review in Journal of bone and mineral metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 86 citations in OpenAlex.
- Effects of High-Impact Exercise on Bone Marker Concentrations During Controlled Low Energy Availability in Recreational Female Runners.Calcified tissue international · 2026Trial
- Expanding roles of N-glycosylation in the endoplasmic reticulum.Trends in cell biology · 2026Review
- Romosozumab Versus Teriparatide for Fracture Prevention, Cardiovascular Events, and Mortality in Osteoporosis: A Propensity Score-Matched Real-World Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Romosozumab in postmenopausal women with classical Osteogenesis imperfecta.Archives of osteoporosis · 2026Article
- The potential role of the gut microbiota in the development of autoantibodies associated with Spondyloarthritis: a narrative review.BMC immunology · 2026Review
- Romosozumab for cancer treatment-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer: a case series.Archives of osteoporosis · 2026Article
- Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Sclerostin in Vascular Calcification: Hypoxia-Driven Regulation and Therapeutic Modulation by Natural Products.Current atherosclerosis reports · 2026Review
- Inhibition of sclerostin activity promotes bone regeneration in experimental periodontal disease: A systematic review and meta-analysis of animal models.Experimental and therapeutic medicine · 2026Article
- Enhancing osteoporosis treatment: emerging roles of engineered exosomes in bone regeneration and repair.Journal of translational medicine · 2026Review
- Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolism.Nature communications · 2026Article
- Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1-34) analogs in women.Biology of sex differences · 2026Article
- Cold exposure and human metabolism: A heterogeneous response across tissues and organs.Temperature (Austin, Tex.) · 2026Review
- Advancing the 3Rs in bone tissue engineering: emergingFrontiers in physiology · 2026Review
- Anabolic effects of Sost deficiency partially offset Opg deficiency-induced catabolism in cortical bone.Journal of bone and mineral metabolism · 2025Article
- Sclerostin's role in bone-muscle crosstalk and osteoporosis pathogenesis.Osteoporosis and sarcopenia · 2025Review
- Plasma proteomic profiles reveal proteins and three characteristic patterns associated with osteoporosis: A prospective cohort study.Journal of advanced research · 2025Article
- Review
- Novel Loss of Function Variant in SOST From Chinese Family Results in Sclerosteosis 1.Molecular genetics & genomic medicine · 2025Article
- Impact of elevated sclerostin levels on bone resorption : unravelling structural changes and mineral metabolism disruption.Bone & joint research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal integrity is maintained by a meticulous balance between bone resorption and bone formation, and recent studies have revealed the essential role of canonical Wnt signaling pathways in maintaining skeletal homeostasis. The SOST gene, which encodes sclerostin, a member of Dan family glycoproteins, was originally identified as the gene responsible for two sclerosing bone dysplasias, sclerosteosis and van Buchem disease. Sclerostin is highly expressed by osteocytes, negatively regulates canonical Wnt signaling pathways by binding to low-density lipoprotein receptor-related protein (LRP) 5/6, and suppresses osteoblast differentiation and/or function. Romosozumab, a specific anti-sclerostin antibody, inhibits sclerostin-LRP5/6 interactions and indirectly activates canonical Wnt signaling pathways and bone formation. This review focuses on the mechanism of action of sclerostin and summarizes clinical studies that demonstrated the efficacy of romosozumab to increase bone mineral density and reduce osteoporotic fractures, as well as its cardiovascular safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.